A tissue engineered polymer wrap designed to reduce vein graft failure rates in patients on hemodialysis for chronic kidney disease (CKD) has won FDA breakthrough device designation. Developed by ...
HOUSTON, TX / ACCESSWIRE / May 17, 2022 / VenoStent, Inc., a clinical-stage tissue engineering company developing bioabsorbable perivascular wraps to improve outcomes in the 5 million vascular ...
Led by seasoned venture capital firms Good Growth Capital and IAG Capital Partners, the Company has completed its Series A financing with $16M to, among other functions, fund their US Pivotal Trial ...
HOUSTON, TX / ACCESSWIRE / January 30, 2024 / VenoStent, Inc., a clinical-stage, venture-backed, therapeutic medical device company developing bioabsorbable wraps to improve outcomes for hemodialysis ...
Venostent Inc. has completed $16 million in series A financing to support a U.S. pivotal trial for bioabsorbable wraps designed to improve outcomes for hemodialysis patients suffering from end-stage ...
NASHVILLE, Tenn., Feb. 23, 2021 /PRNewswire-PRWeb/ -- VenoStent, a Houston-based advanced materials company, today announced $2.3M in seed funding. The company leverages its unique polymer engineering ...
Designation to promote more rapid Agency and market access for VenoStent HOUSTON, TX / ACCESSWIRE / May 17, 2022 / VenoStent, Inc., a clinical-stage tissue engineering company developing bioabsorbable ...
VenoStent is conducting a 200-subject, prospective, one-to-one randomized controlled trial in dialysis access HOUSTON, TX / ACCESSWIRE / January 30, 2024 / VenoStent, Inc., a clinical-stage, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results